Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>In the first quarter of 2024, Merck & Co. demonstrated a strong start with robust growth across its business.</li><li>This was mainly led by the oncology and vaccines segments, where sales of KEYTRUDA and GARDASIL respectively saw significant increases.</li><li>Merck's first quarter results reflect the robust demand for its innovative portfolio, which has led to the company updating their full year guidance.</li></ul>

In the first quarter of 2024, Merck & Co. demonstrated a strong start with robust growth across its business.This was mainly led by the oncology and vaccines segments, where sales of KEYTRUDA and GARDASIL respectively saw significant increases.Merck's first quarter results reflect the robust demand for its innovative portfolio, which has led to the company updating their full year guidance.

Merck & Co.: Progress in Personalized Cancer Vaccine Collaborated with Moderna & Other Major Drivers

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/samsung-biologics-co-ltd" target="_blank" data-smartkarma-citation="entities:22932:1" rel="noopener">Samsung Biologics (207940 KS)</a> has signed the largest ever single CMO contract worth KRW1.46T ($1.1B) with an undisclosed U.S.-based pharmaceutical company. The contract value represents ~40% of 2023 standalone revenue.</li>
<li>Within the first half of the year, Samsung Biologics has secured order worth of KRW2.6T, compared with order win of KRW3.5T in full-year 2023.</li>
<li>Samsung Bioepis has received FDA approval for Stelara biosimilar Pyzchiva, which is expected to marketed in early 2025. So far, the FDA has approved two other biosimilars of Stelara.  </li>
</ul>



Samsung Biologics (207940 KS) has signed the largest ever single CMO contract worth KRW1.46T ($1.1B) with an undisclosed U.S.-based pharmaceutical company. The contract value represents ~40% of 2023 standalone revenue.
Within the first half of the year, Samsung Biologics has secured order worth of KRW2.6T, compared with order win of KRW3.5T in full-year 2023.
Samsung Bioepis has received FDA approval for Stelara biosimilar Pyzchiva, which is expected to marketed in early 2025. So far, the FDA has approved two other biosimilars of Stelara.  


Samsung Biologics (207940 KS): Gaining Momentum on New Approval and Contract Wins; Hold Shares

<ul><li>In the Q4 earnings, Merck & Co.</li><li>reported a strong financial performance, underpinned by a robust demand for their innovative portfolio, including Keytruda, Welireg, and Gardasil, among others.</li><li>The company has embarked on various collaborations further bolstering its product pipeline with a promising line of innovations.</li></ul>

In the Q4 earnings, Merck & Co.reported a strong financial performance, underpinned by a robust demand for their innovative portfolio, including Keytruda, Welireg, and Gardasil, among others.The company has embarked on various collaborations further bolstering its product pipeline with a promising line of innovations.

Merck & Co: A Story Of Significant Progress & Execution Across Therapeutic Areas! - Major Drivers

Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Thematic (Sector/Industry)

<ul>
<li>We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.</li>
<li>We recapped our IOC of Ainos, Inc. (AIMD) in a FlashCast Podcast. Those interested can listen to the episode on Apple Podcasts or Spotify.</li>
<li>Alnylam Pharmaceuticals, Inc. (ALNY) reported strong vutrisiran Phase 3 HELIOS-B results for ATTR-CM, showing a significant 28% reduction in the primary composite endpoint of mortality and CV events for all patients (HR=0.718, p=0.0118) and a 33% reduction for the mono subset (HR=0.672, p=0.0162) versus placebo. </li>
</ul>


We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.
We recapped our IOC of Ainos, Inc. (AIMD) in a FlashCast Podcast. Those interested can listen to the episode on Apple Podcasts or Spotify.
Alnylam Pharmaceuticals, Inc. (ALNY) reported strong vutrisiran Phase 3 HELIOS-B results for ATTR-CM, showing a significant 28% reduction in the primary composite endpoint of mortality and CV events for all patients (HR=0.718, p=0.0118) and a 33% reduction for the mono subset (HR=0.672, p=0.0162) versus placebo. 


<ul><li>Merck delivered an all-around beat in the quarter, making excellent strides in advancing compelling science that will contribute to meeting the world's most critical unmet medical needs.</li><li>Concerning their research organization, Merck's encouraging late-stage pipeline keeps proving beneficial for patients with a wide spectrum of ailments.</li><li>In oncology, Merck highlighted information from ASCO's extensive pipeline, including evidence for KEYTRUDA in lung cancer that is in an earlier stage.</li></ul>

Merck delivered an all-around beat in the quarter, making excellent strides in advancing compelling science that will contribute to meeting the world's most critical unmet medical needs.Concerning their research organization, Merck's encouraging late-stage pipeline keeps proving beneficial for patients with a wide spectrum of ailments.In oncology, Merck highlighted information from ASCO's extensive pipeline, including evidence for KEYTRUDA in lung cancer that is in an earlier stage.

Merck & Co. Inc.: Setting New Standards in Oncology & Pneumococcal Immunization! - Major Drivers

United States

Merck & Co., Inc.  is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Merck & Co (MRK US)

Merck & Co.: Progress in Personalized Cancer Vaccine Collaborated with Moderna & Other Major Drivers

In the first quarter of 2024, Merck & Co. demonstrated a strong start with robust growth across its business. This was mainly led by the...

Baptista Research

Samsung Biologics (207940 KS): Gaining Momentum on New Approval and Contract Wins; Hold Shares

Samsung Biologics signs $1.1B CMO contract, representing 40% of 2023 revenue. Samsung Bioepis receives FDA approval for Stelara biosimilar...

Tina Banerjee

Merck & Co: A Story Of Significant Progress & Execution Across Therapeutic Areas! - Major Drivers

In the Q4 earnings, Merck & Co. reported a strong financial performance, underpinned by a robust demand for their innovative portfolio,...

Baptista Research

Biopharma Week in Review - July 1, 2024

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A.

Water Tower Research

Merck & Co. Inc.: Setting New Standards in Oncology & Pneumococcal Immunization! - Major Drivers

Merck delivered an all-around beat in the quarter, making excellent strides in advancing compelling science that will contribute to meeting the...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Merck & Co.: Progress in Personalized Cancer Vaccine Collaborated with Moderna & Other Major Drivers

In the first quarter of 2024, Merck & Co. demonstrated a strong start with robust growth across its business. This was mainly led by the...

Baptista Research

Samsung Biologics (207940 KS): Gaining Momentum on New Approval and Contract Wins; Hold Shares

​Samsung Biologics signs $1.1B CMO contract, representing 40% of 2023 revenue. Samsung Bioepis receives FDA approval for Stelara biosimilar...

Tina Banerjee

Merck & Co: A Story Of Significant Progress & Execution Across Therapeutic Areas! - Major Drivers

In the Q4 earnings, Merck & Co. reported a strong financial performance, underpinned by a robust demand for their innovative portfolio,...

Baptista Research

Biopharma Week in Review - July 1, 2024

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A.

Water Tower Research

Merck & Co. Inc.: Setting New Standards in Oncology & Pneumococcal Immunization! - Major Drivers

Merck delivered an all-around beat in the quarter, making excellent strides in advancing compelling science that will contribute to meeting the...

Baptista Research

Samsung Biologics signs $1.1B CMO contract, representing 40% of 2023 revenue. Samsung Bioepis receives FDA approval for Stelara biosimilar...